Application of human epididymis protein 4 and CA125 joint detection in ovarian neoplasms and the correlation between human epididymis protein 4 and pathological type of ovarian neoplasms

Abstract

Objective To explore the application value of human epididymis protein (HE)4 and carbohydrate antigen 125 (CA125) joint detection in the diagnosis of ovarian cancer and the correlation between HE4 level and pathological types of ovarian cancer. Methods From December 2013 to February 2014, a total of 137 cases of inpatients with ovarian tumor who would receive operation in Shangqiu First People's Hospital in Henan Province were selected into this study. According to the postoperative pathological examination results, they were divided into ovarian cancer group (n=54) and benign tumor group (n=83). During the same period 76 cases of health women who took health examination in the same hospital were selected as control group. The levels of serum HE4 and CA125 in three groups were respectively measured by enzyme linked immunosorbent assay and electro chemiluminescence immunoassay, and the testing results were statistically analyzed. The inclusion criteria of ovarian cancer group and benign tumor group in this study: confirmed by chest X-ray and ultrasonography, there was no tumor in other parts of the body; the exclusion criteria: patients with endometriosis and pelvic inflammatory disease detected by related examinations were excluded, and complicated with essential hypertension, diabetes and other chronic diseases, with liver, renal or cardiac dysfunction, and with tumors in other parts of the body and family history of cancer were excluded. The difference in age structure of the three groups was not statistically significant (P>0.05). The procedure that this study followed met the ethical standards made by Institutional Review Board of Shangqiu First People's Hospital in Henan Province and approved by the committee. Grouping had the consent of study subjects, and the clinical study letters of consent were signed. Results The serum HE4 and CA125 levels in the ovarian cancer group were (335.25±314.02)pmol/L and (2215.25±1234.71)U/mL, respectively, which were significantly higher than those(45.36±8.14)pmol/L and (34.26±9.25)U/mL in benign tumor group, and (44.16±6.33)pmol/L, (27.85±8.25)U/mL in control group, and the differences were statistically significant (t=12.351, 12.407, 16.124, 15.426; P<0.01). The sensitivity of HE4 and CA125 joint detection in the diagnosis of ovarian cancer was higher than that CA125 or HE4 detection alone, and the differences were statistically significant (t=4.788, 3.927; P<0.05). Conclusions The joint detection of serum HE4 and CA125 significantly improves the sensitivity in diagnosis of ovarian cancer, which is of great significance to the differential diagnosis of benign and malignant ovarian tumors. Key words: Human epididymis protein; Carbohydrate antigen 125; Ovarian neoplasms; Pathological type